Abstract
Betaxolol, a long-acting β-adrenergic blocker that enters the central nervous system, was examined for therapeutic effects on the persistent anxiety of anxiety disorders. Prior studies of β-blockers examined only agents that were short-acting or did not enter the brain. Betaxolol was administered to 31 patients in open trials. Of 13 outpatients, 11 had generalized anxiety disorder (GAD) and 2 had adjustment disorder with anxiety. Five with GAD had concurrent panic disorder. Of 18 inpatients, 16 had GAD and 2 had adjustment disorder with anxiety. Betaxolol doses were increased until the patient responded or declined further dosage. Severity was rated on a 4-point global scale. Before betaxolol, all were moderately or severely ill. In all patients with panic disorder panic attacks stopped within 2 days (p<0.001). Anxiety decreased to no more than marginally ill in 85% of outpatients (p<0.0001) and all inpatients (p<0.0001). Betaxolol doses were usually 5 mg once or twice daily; four inpatients took 10 to 20 mg twice daily. In sum, betaxolol administration was rapidly followed by improvements that were easily noticed by the doctor, even in patients with longstanding anxiety and obsessive–compulsive personality disorder. Preliminary observations in posttraumatic stress disorder are similar.
Similar content being viewed by others
REFERENCES
Kawachi I, Sparrow D, Vokonas PS, Weiss ST: Symptoms of anxiety and risk of coronary heart disease. Circulation 1994; 90:2225–2229
Kawachi I, Colditz GA, Ascheno A, Rimm EB, Giovannucci E, Stampfer MJ, Willett WC: Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 1994; 89:1192–1197
Ketterer M: Presentation at American Psychosomatic Society, Santa Fe, NM, Mar 21, 1997 (reported by Reuters Health Information Service)
Eaker ED, Pinsky J, Castelli WP: Myocardial infarction and coronary death among women: Psychosocial predictors from a 20-year follow-up of women in the Framingham Study. Am J Epidemiol 1992; 135:854–864
Fawcett J, Scheftner W, Clark D, Hedeker D, Gibbons R, Coryell W: Clinical predictors of suicide in patients with major affective disorders: A controlled prospective study. Am J Psychiatry 1987; 144:35–40
Chance S, Kaslow N, Baldwin K: Anxiety and other predictors of severity of suicidal intent in urban psychiatric inpatients. Hosp Commun Psychiatry 1994; 45:716–718
Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kessler KS: Lifetime and 12-month prevalence of DSM-3-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51:8–19
Brown TA, Barlow DH, Liebowitz MR: The empirical basis of generalized anxiety disorder. Am J Psychiatry 1994; 151:1272–1280
American Psychiatric Association: DSM-IV Diagnostic and Statistical Manual of Psychiatry, 4th ed. Washington, DC: American Psychiatric Association; 1994
Lader M: Beta-adrenoceptor antagonists in psychiatry: An update. J Clin Psychiatry 1988; 49:213–223
Famularo R, Kinscherff R, Fenton T: Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. Am J Dis Child 1988; 142:1244–1247
Hayes PE, Schulz SC: Beta-blockers in anxiety disorders. J Affect Dis 1987; 13:119–130
Bright RA, Everitt DE: Beta-blockers and depression. Evidence against an association. JAMA 1992; 267:1783–1787
Gerstman BB, Jolson HM, Bauser M, et al.: The incidence of depression in new users of beta-blockers and selected antihy-pertensives. J Clin Epidemiol 1996; 29:809–815
Rickels K, Csanalosi IB, Chung HR, Avallone MF: The beta-blocker atenolol in anxiety: A controlled study. Current Ther Res 1986; 40:149–155
Lydiard RB, Roy-Byrne PP, Ballenger JC: Recent advances in the psychopharmacological treatment of anxiety disorders. Hosp Commun Psychiatry 1988; 39:1157–1165
Pollock MH: Progress notes, Newslett Am Soc Clin Pharmacol 1997; 8:6
Schweizer R, Roth WT, Elbert T: Effect of two beta-blockers on stress during mental arithmetic. Psychopharmacology 1991; 105:573–577
Durel LA, Krantz DS, Barrett JE: The antianxiety effect of beta-blockers on punished responding. Pharm Biochem Behav 1986; 25:371–374
Gorman JM, Gorman LK: Drug treatment of social phobia. J Affect Dis 1987; 13:183–192
Rangno RE, Langlois S: Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. Br J Clin Pharmacol 1982; 13(suppl 2):345S-351S
Mulcahy D: Circadian variations in cardiovascular disease: Implications for treatment. Br J Clin Pract Symp Suppl 1994; 73:31–36
Cooper SJ, Kelly CB, McGilloway S, Gilliland A: Beta 2-adrenoceptor antagonism in anxiety. Eur Neuropsychopharm 1990; 1:75–77
Monti JM, Jantos H: Stereoselective antagonism by the pindolol enantiomers of 8-OH-DPAT-induced changes of sleep and wakefulness. Neuropharmacology 1994; 33:705–708
Danjou P, Puech A, Warot D, Benoit JF: Lack of sleep-inducing properties of propranolol (80 mg) in chronic insomniacs previously treated by common hypnotic medications. Int Clin Psychopharmacol 1987; 2:135–140
Saunders J, Gomeni R, Kilborn JR, Morselli PL, Sonksen PH: A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycemia. Eur J Clin Pharmacol 1981; 21:177–184
Hewitt PL, Flett GL: Dimensions of perfectionism, daily stress, and depression: A test of the specific vulnerability hypothesis. J Abnorm Psychology 1993; 102:58–65
Przegalinski E, Tatarczynska E, Chojnacka-Wojcik E: The role of hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptors in the anticonflict activity of beta-adrenoceptor antagonists. Neuropharmacology 1995; 34:1211–1217
Cooper JR, Bloom FE, Roth RH: The Biochemical Basis of Neuropharmacology, 7th ed. New York: Oxford Press; 1996; 273–278
Klein DF: False suffocation alarms, spontaneous panics, and related conditions: An integrative hypothesis. Arch Gen Psychiatry 1993; 50:306–317
Davidov ME, Glazer N, Wollam G, Zager PG, Cangiano J: Comparison of betaxolol, a new beta 1-adrenergic antagonist, to propranolol in the treatment of mild to moderate hypertension. Am J Hypertens 1988; 1 (3, Pt 3):206S-210S
Ross CA, Matas M: A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Can J Psychiatry 1987; 32:351–355
Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, Quadrino LM, Heninger GR: J Clin Psychiatry 1986; 47:580–586
Goa KL, Ward A: Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 1986; 32:114–129
Brodsky MA, Sato DA, Isen LT, Wolff LJ, Allen BJ: Ventricular tachyrhythmia associated with psychological stress. JAMA 1987; 257:2064–2067
Bortolotto LA, Ramires JA, Serrano Junior CV, Cesar LA, Solimene MC, da-Luz PL, Pileggi F: Beneficial effect of long-term use of a beta-blocker in patients before acute myocardial infarction. Braz J Med Biol Res 1995; 28:637–642
O'Hanlon JF, Blaauw GJ, Riemersma JBJ: Diazepam impairs lateral position control in highway driving. Science 1982; 217:79–81
Cummings JL. Anatomic and behavioral aspects of frontal-subcortical circuits. Ann NY Acad Sci 1995; 769:1–13
Chierichetti SM, Moise G, Galeone M, Fiorella G, Lazzari R. Beta-blockers and psychic stress: A double-blind placebo-controlled study of bopindolol vs lorazepam and butalbital in surgical patients. Int J Clin Pharmacol Ther Toxicol 1985; 23:510–514
Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S: Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharm 1994; 14:90–98